Dear Surabhi,
A proposal to enhance Dash Bio's quality and validation capabilities with agentic AI
I hope you are doing well and that things are going smoothly as you ramp up Dash's new lab footprint and assay platforms in Waltham. I've been following Dash Bio's progress and am genuinely impressed by how you've combined GLP/GCP-grade quality with an automated, tech-first bioanalysis platform that can turn around ELISA/MSD, LC‑MS, qPCR, ddPCR and related assays in days instead of months, while publishing transparent, fixed pricing and even offering a self-service quoting tool. As someone who has spent the last several years focused on GxP validation and AI in regulated environments, your background in global quality systems, supplier management, and Veeva Vault really stood out to me because it's exactly the kind of mindset that makes AI useful rather than risky.
Introduction to xLM Continuous Intelligence
By way of introduction, I lead xLM Continuous Intelligence, where we build agentic AI applications specifically for regulated life sciences. Our platform is used to automate GxP validation, generate and maintain living validation packages, and orchestrate multi-agent workflows that sit "on top of" existing systems (e.g., LIMS, QMS, eLN, MES, lab automation) without breaking data integrity or auditability. We've focused on making AI behave like a compliant digital team member: every action is logged, explainable, and tied back to requirements, test evidence, and change controls, which tends to resonate with quality leaders who live in inspection-readiness mode.
Opportunities for Dash Bio
Looking at Dash's model—high-throughput, robotics-driven bioanalysis, fixed-pricing, and guaranteed timelines—there are a few concrete places where xLM's agentic apps could help you extend that advantage:
Vendor and GxP Supplier Oversight
Vendor and GxP supplier oversight for your own critical suppliers (reagents, kits, instruments, software): AI agents that continuously monitor qualification status, incoming changes, audit outputs, and commitments, and auto-generate QMR/QBR-ready metrics and summaries.
Validation and Re-validation
Validation and re-validation of your custom-built LIMS, robotic workflows, and new assay platforms (e.g., new high-resolution LC‑MS capabilities): agents that keep URS/FS/DS, risk assessments, test scripts, and evidence synchronized with each release so you stay ahead of inspectors as you scale the platform.
Automated Quality Copilots
Automated "quality copilots" for Dash's internal teams: sidecar agents that watch day-to-day lab operations and documentation (e.g., method development/validation packages, deviations, CAPAs, change controls) and flag gaps, suggest standard text that aligns with your own SOPs, and prepare inspection-ready narratives.
A Focused Approach
I know you've already leveraged AI within Veeva Vault in prior roles and that you care deeply about both efficiency and compliance, so my goal would not be to add yet another generic AI tool, but to explore a small, tightly scoped pilot where we prove clear impact on quality workload and inspection readiness without increasing your risk surface.

Pilot Example: We could start with an agent that automatically assembles and maintains validation and change-control dossiers for one of your robotic assay platforms (say, a specific LC‑MS or qPCR workflow), then expand to a broader quality and supplier-oversight agent if that proves valuable.
Next Steps
If you're open to it, I'd love to schedule 30 minutes to learn more about how Dash is currently handling validation, quality systems, and AI internally, and to share a brief demo of how our agentic apps handle GxP validation and supplier oversight in practice. If it makes more sense, I'm also happy to first connect with Dave or Ely and frame this around how AI-enabled validation and quality could further differentiate Dash's bioanalysis platform for sponsors who are already excited about your speed and transparency.
Thanks for considering this, and congratulations again on the growth at Dash
What you and the team are building is exactly the kind of modern infrastructure our industry needs.
Best regards,
Nagesh Nama
CEO, xLM Continuous Intelligence
Get in Touch
Appendix A: xLM Company Overview
Company Details:
Company Name: xLM Continuous Intelligence
Headquarters: Jacksonville, Florida, USA
Founded: 1996
CEO: Mr. Nagesh Nama
Mission:
Transform GxP operations in life sciences through AI-powered continuous intelligence, enabling companies to innovate faster while maintaining rigorous compliance.
Platform: ContinuousOS™
Purpose-built suite of AI applications for pharmaceutical manufacturing:
  • cIV (Continuous Intelligent Validation)
  • cPdM (Continuous Predictive Maintenance)
  • cTM (Continuous Temperature Mapping)
  • cSM (Continuous Service Management)
  • cEMS (Continuous Environmental Monitoring)
  • Plus: cIGA, cRPA, cDIPM, cDM, cALM, cRM, cRMM, cMP, cMTR, cITOM
Regulatory Foundation:
  • QMS based on ISO 9001:2015, GAMP 5, ASTM E 2500
  • 21 CFR Part 11 compliant (electronic records and signatures)
  • EudraLex Annex 11 compliant (computerized systems)
  • ALCOA+ data integrity principles
  • FDA/EMA guidance on AI in pharma operations
Customer Base:
Pharmaceutical, biotech, and medical device manufacturers (specific customers available under NDA)
Differentiators:
  • Only platform with agentic AI for autonomous validation workflows
  • Continuous validation model (not point-in-time)
  • Managed service delivery (customers don't validate the validator)
  • Guaranteed ROI (<3 months)
  • Purpose-built for GxP (not adapted from generic software)
Appendix B: Competitive Landscape
xLM Unique Position:
  • Only vendor combining AI-powered validation + predictive maintenance + temperature mapping in integrated platform
  • Continuous validation model (ongoing compliance, not periodic revalidation)
  • Managed service delivery (fastest time-to-value, no customer validation burden)
  • GxP-native design (not adapted from generic software)
  • Guaranteed ROI (low risk for customer)
Disclaimer
This proposal is confidential and intended solely for Dash Bio's' leadership team. Unauthorized distribution is prohibited.
All financial projections and ROI estimates are based on typical xLM client results and industry benchmarks. Actual results may vary based on Dash Bio's specific operational context. XLM guarantees <3-month ROI payback; if not achieved, fee credits will be applied as contractually agreed.
xLM Continuous Intelligence reserves the right to update this proposal based on additional discovery and alignment discussions with Dash Bio.